39 completed, 5 unknown, 3 not yet recruiting, 3 terminated. 19 Phase 1, 17 Phase 2, 4 Not applicable, 3 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 18, Withdrawn 1 |
| Phase 2 | 17 | Completed 12, Terminated 3, Withdrawn 2 |
| Not applicable | 4 | Active not recruiting 2, Completed 2 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 4 | 1 | Withdrawn 1 |
Follow HCV Infection: new trials by email Literature Review of HCV Infection trials Research Report on HCV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort" Blood sampling, Umbilical cord blood sampling, Survey using a questionnaire - HIV Infection, HBV Infection | Not yet recruiting | ANRS, Emerging Infectious Diseases | 5160 | 2026-02-01 | 2026-02-17 | |
| Hepatitis B and C Within the Chinese Community in Milan HBV (Hepatitis B Virus), HCV Infection | Not yet recruiting | IRCCS Ospedale San Raffaele | 1000 | 2025-12-01 | 2025-11-21 | |
| Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV HCV Infection | Recruiting | University of Seville | 728 | 2025-04-30 | 2025-04-15 | |
| The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C - HCV Infection, HCV Elimination | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 200000 | 2025-04-25 | 2025-04-30 | |
| Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia Sofosbuvir/Daclatasvir - HCV Infection | Not applicable | Active not recruiting | ANRS, Emerging Infectious Diseases | 21000 | 2023-08-07 | 2025-12-04 |
| APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies Choice of STBBI test(s) - HIV Infections, HCV Infection | Not applicable | Active not recruiting | Memorial University of Newfoundland | 407 | 2022-12-01 | 2024-12-02 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) Glecaprevir/pibrentasvir - HCV Infection | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2021-10-01 | 2021-05-06 | |
| A Community-based Intervention Among Active Drug Users in Montpellier HCV screening, Diagnosis of hepatitis C, HCV treatment - Drug Use, HCV Infection | Not applicable | Completed | ANRS, Emerging Infectious Diseases | 554 | 2020-09-18 | 2022-07-22 |
| Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) Health Linkage, Overdose Education - Substance Use, HIV Infections | Not applicable | Completed | April M Young | 234 | 2019-11-15 | 2023-12-21 |
| HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST) HIV Seropositivity, HCV Infection | Unknown | ANRS, Emerging Infectious Diseases | 1098 | 2019-09-01 | 2019-10-22 | |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
| Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection SOF+DCV+CDI-31244, SOF+DCV+CDI-31244+ASV - HCV Infection | Phase 2 | Withdrawn | Humanity & Health Medical Group Limited | 2019-05-01 | 2020-05-07 | |
| Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid HCV rapid test - HCV Infection, HIV Infections | Completed | Hospital Universitario Infanta Leonor | 2001 | 2019-02-15 | 2021-02-09 | |
| Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C Optical coherence tomography angiography, Sofosbuvir (Sovaldi) - HCV Infection | Unknown | Mohamed Saad | 30 | 2019-02-10 | 2019-11-12 | |
| Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection GLS-6150 - HCV Infection | Phase 1 | Completed | GeneOne Life Science, Inc. | 32 | 2018-09-04 | 2020-05-27 |
| Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection SH229, Placebos - HCV Infection | Phase 1 | Completed | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 30 | 2018-07-07 | 2018-08-28 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major | Phase 3 | Unknown | Ain Shams University | 24 | 2018-06-11 | 2023-03-06 |
| Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study HCV serology - HCV Infection | Unknown | Asociacion para el Estudio del Higado | 293 | 2018-04-01 | 2018-04-03 | |
| Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules - HCV Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 57 | 2018-01-25 | 2023-05-31 |
Showing 20 of 56. Sign in to see all of them.
Hepatitis C (56) · HIV Infections (5) · Hepatitis (4) · Hepatitis C, Chronic (3) · Fibrosis (2) · Hepatitis B (2) · Arbovirus Infections (1) · Bronchiolitis Obliterans Syndrome (1) · Coinfection (1) · Disease (1) · Drug Overdose (1) · HIV Seropositivity (1) · Liver Cirrhosis, Experimental (1) · Neurocognitive Disorders (1) · Sexually Transmitted Diseases (1)
Blood-Borne Infections (56) · Communicable Diseases (56) · Digestive System Diseases (56) · Flaviviridae Infections (56) · Hepatitis, Viral, Human (56) · Infections (56) · Liver Diseases (56) · RNA Virus Infections (56) · Virus Diseases (56) · Hepatitis (52) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Immune System Diseases (7) · Genital Diseases (6) · Immunologic Deficiency Syndromes (6)
Ribavirin (6) · dasabuvir (5) · ledipasvir, sofosbuvir drug combination (5) · Sofosbuvir (4) · Ritonavir (3) · paritaprevir (3) · peginterferon alfa-2a (3) · voxilaprevir (3) · AT-511 (2) · Ketoconazole (2) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (2) · daclatasvir (2) · peginterferon alfa-2b (2) · tegobuvir (2) · ABT-072 (1)
Gilead Sciences (13) · Abbott (7) · ANRS, Emerging Infectious Diseases (4) · AbbVie (2) · Atea Pharmaceuticals, Inc. (2) · Hoffmann-La Roche (2) · Merck Sharp & Dohme LLC (2) · AbbVie (prior sponsor, Abbott) (1) · Ain Shams University (1) · Alexion Pharmaceuticals, Inc. (1) · April M Young (1) · Asociacion para el Estudio del Higado (1) · Corporacion Parc Tauli (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · French National Agency for Research on AIDS and Viral Hepatitis (1)
United States (27) · France (8) · Germany (8) · Puerto Rico (8) · Belgium (4) · New Zealand (4) · Canada (3) · Netherlands (3) · Poland (3) · Spain (3) · United Kingdom (3) · Cambodia (2) · Egypt (2) · Australia (1) · China (1)
Daniel Cohen, MD (3) · Isabelle A Gaultier, M.S., IBMH (2) · Adebayo A Lawal, MD (1) · Andrew Campbell, MD (1) · April M Young, PhD, MPH (1) · Arthur Y Kim, M.D. (1) · Daniel E Cohen, MD (1) · David Oldach, MD (1) · Deborah C. Molrine, MD (1) · Diana Brainard, MD (1) · Didier Samuel, Pr (1) · Elana Rosenthal, MD (1) · Francoise Stoll-Keller, MD (1)
PMID 23356386, PMID 23768747, PMID 23877691, PMID 25451055, PMID 25773757, PMID 25846014, PMID 26597291, PMID 26710243, PMID 27554134, PMID 31995556, PMID 32531259, PMID 34186262, PMID 35774932, PMID 36790337, PMID 37720025, PMID 37946233
2015 (3), 2014 (2), 2019 (2), 4UH3DA044798-03 (1)